Heterobimetallic compounds are designed to harness chemotherapeutic traits of distinct
metal species into a single molecule. The ruthenium–gold (Ru–Au) family of compounds …

The syntheses, structures, and chemotherapeutic activities of Ag (I)‐, Au (I)‐, and Ru (II)‐
complexes ligated to a novel N‐heterocyclic carbene ligand, 2‐(4‐nitrophenyl) imidazo [1, 5 …

We describe a versatile and quick route to cationic gold (I) complexes containing N-
heterocyclic carbenes and a second ancillary ligand (such as phosphanes, phosphites …

Ruthenium-based compounds show strong potential as anti-cancer drugs and are being
investigated as alternatives to other well-established metal-based chemotherapeutics. The …

Following recent work on heterometallic titanocene–gold complexes as potential
chemotherapeutics for renal cancer, we report here on the synthesis, characterization and …

The synthesis, characterization, and biological evaluation of novel Ru (II)-and Au (I)-N-
heterocyclic carbenes is reported. The NHC-ruthenium (II) complexes (1–6) were …

A series of organometallic AuI N‐heterocyclic carbene (NHC) complexes was synthesized
and characterized for anticancer activity in four human cancer cell lines. The compounds' …

Both metal complexes and organic molecules are widely used for the treatment of various
diseases including cancer–in addition to surgery and radiotherapy. Recent years have …

While N-heterocyclic carbenes (NHC) are ubiquitous ligands in catalysis for organic or
industrial syntheses, their potential to form transition metal complexes for medicinal …

Organometallic gold complexes with N‐heterocyclic carbene (NHC) ligands have been
demonstrating promising properties as novel anticancer agents. Gold (I) NHC complexes …